Notes on the Laos Lucius version of Voranigo
When using Voranigo, special attention should be paid to drug interactions, liver function monitoring, and medication risks for special populations. In clinical applications, treatment plans should be adjusted according to individual patient conditions and adverse reactions should be closely monitored.
1. Drug interactions
(1) CYP3A4 inhibitors: When used in combination with potent CYP3A4 inhibitors, the dosage should be reduced to 160mg twice daily to avoid toxicity caused by high blood drug concentrations.
(2) CYP3A4 inducer: Avoid using strong inducers in combination, which may lead to reduced efficacy. When necessary, increase the dosage and monitor the efficacy.
2. Liver function monitoring
(1) Basic assessment: ALT/AST/bilirubin levels need to be tested before medication, and dosage adjustment is required for patients with moderate to severe liver dysfunction.
(2) Regular follow-up: During the treatment period, monitor liver function every 2-4 weeks. If ALT/AST>3 times the normal value, medication should be suspended.
3. Hematological toxicity
(1) White blood cell control: Before administration, it is necessary to confirm that the white blood cell count is less than 25Gi/L, otherwise treatment will be delayed until it meets the standard.
(2) Platelet monitoring: Treatment should be interrupted when grade 3 or above thrombocytopenia occurs, and the dosage should be reduced and restarted after recovery.
4. Medication for special populations
(1) Pregnancy period: Animal studies have shown embryotoxicity, and women of childbearing age need to take effective contraceptive measures until one month after the last dose.
(2) Breastfeeding period: Breastfeeding is prohibited during medication, as the medication may be secreted through breast milk.
(3) Children: No safety data available, strict assessment of risk benefit ratio is required.
5. Other important warnings
(1) QT interval prolongation: Regularly monitor electrocardiogram and avoid combination with other QT prolonging drugs.
(2) Allergic reactions: permanent discontinuation of medication is required for hypersensitivity reactions such as vascular edema.
(3) Storage requirements: Store in the dark below 25 ℃, and use up within 30 days after opening.
Disclaimer：《Notes on the Laos Lucius version of Voranigo》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！